SCHEMBL1009538

SCHEMBL1009538

CC(C(=O)O)c1c(Cl)nc(Cc2ccc(N(C)C(=O)c3ccc(Cl)cc3)cc2)nc1N(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TBXA2R P21731 1/20 0.37
PTGDR Q13258 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
CHEK2 O96017 1/20 0.36
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MCHR1 Q99705 1/20 0.34
ACACB O00763 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
INSR P06213 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012425 0.82 TBXA2R (0.41) ALDH1A1SMN1; SMN2TBXA2RPTGDRPTGDR2
SCHEMBL1010306 0.82 PTGDR2 (0.51) ALDH1A1SMN1; SMN2TBXA2RPTGDRPTGDR2
SCHEMBL12569006 0.78 TBXA2R (0.42) ALDH1A1SMN1; SMN2TBXA2RPTGDRPTGDR2
SCHEMBL1009772 0.76 NR1H4 (0.48) TBXA2RPTGDRPTGDR2NR1H4
SCHEMBL8738530 0.75 PTGDR2 (0.49) ALDH1A1SMN1; SMN2TBXA2RPTGDRPTGDR2
SCHEMBL1010222 0.73 TBXA2R (0.38) ALDH1A1TBXA2RPTGDRPTGDR2EGLN1
SCHEMBL1009043 0.70 COPS5 (0.40) ALDH1A1EGLN1MAPTL3MBTL1LMNA
SCHEMBL1922623 0.69 POLB (0.40) SMN1; SMN2
SCHEMBL1010635 0.69 POLB (0.40) SMN1; SMN2
SCHEMBL1010897 0.69 PTGDR2 (0.72) TBXA2RPTGDRPTGDR2NR1H4MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960393-B2 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
EP-1633726-B1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS INC (US) 2011-01-05 EP disclosed